StocksMedium•11 November 2026•
1 min read
Aspen Pharmacare Wins Approval for Generic Semaglutide in Brazil and South Africa
Key Facts
1Aspen Pharmacare has secured regulatory approvals to launch a generic version of semaglutide in Brazil and South Africa.
Aspen Pharmacare has secured regulatory approvals to launch a generic version of semaglutide in Brazil and South Africa. Reuters reported that the company received clearance to market the generic form of the active ingredient found in popular weight-loss and diabetes treatments.
The move introduces competition for Novo Nordisk's Wegovy and Ozempic in emerging markets as regulatory pathways for generics open. This expansion occurs amid varying economic conditions in these regions, with South Africa reporting a 33.7% unemployment rate on November 10, 2026, and Brazil recording a trade balance of 9.32 billion on November 6, 2026.